RT Journal Article
T1 Nanotechnology-based drug delivery to improve the therapeutic benefits of NRF2 modulators in cancer therapy
A1 Sezgin Bayindir, Zerrin
A1 Losada Barreiro, Sonia
A1 Bravo Díaz, Carlos Daniel
A1 Sova, Matej
A1 Kristl, Julijana
A1 Saso, Luciano
K1 3207.03 Carcinogénesis
K1 3208.06 Quimioterapia
K1 3208.02 Acción de Los Medicamentos
AB The disadvantages of conventional anticancer drugs, such as their low bioavailability, poor targeting efficacy, and serious side effects, have led to the discovery of new therapeutic agents and potential drug delivery systems. In particular, the introduction of nano-sized drug delivery systems (NDDSs) has opened new horizons for effective cancer treatment. These are considered potential systems that provide deep tissue penetration and specific drug targeting. On the other hand, nuclear factor erythroid 2-related factor 2 (NRF2)-based anticancer treatment approaches have attracted tremendous attention and produced encouraging results. However, the lack of effective formulation strategies is one of the factors that hinder the clinical application of NRF2 modulators. In this review, we initially focus on the critical role of NRF2 in cancer cells and NRF2-based anticancer treatment. Subsequently, we review the preparation and characterization of NDDSs encapsulating NRF2 modulators and discuss their potential for cancer therapy.
PB Antioxidants
SN 20763921
YR 2021
FD 2021-04-27
LK http://hdl.handle.net/11093/2797
UL http://hdl.handle.net/11093/2797
LA eng
NO Antioxidants, 10(5): 685 (2021)
DS Investigo
RD 13-dic-2024